phrma logo

PhRMA

PhRMA Sites

Login

Explore Member-Only Resources

Access exclusive advocacy, policy, and research materials through the member site.

Login now

About

About

Our Agenda

Our Agenda

Policy Issues

We believe that patients should have access to innovative medicines.

Learn More

Innovation Ecosystem

Intellectual Property

Research & Development

Future of Medicine

Government Price Setting

International

Innovation Ecosystem

Patient Access & Affordability

PBMs & Middlemen

Hospitals and 340B

Insurance Coverage

Cost of Medicines

Medicare & Medicaid

Patient Access & Affordability

Resources

Our mission is to conduct effective advocacy for public policies that encourage the discovery of important, new medicines for patients by biopharmaceutical research companies.

Learn More

Resources

Resources

Newsroom

Newsroom

Blog

Blog

America's Medicines

PhRMA Foundation

PhRMA Foundation Logo

Voters for Cures

VotersForCures.org Logo

Working for Cures

workersforcures.org logo

This is Innovation

Innovation.org logo

View More

Search in PhRMA

Find resources, news, and articles related to policy issues and scientific innovation.

What are you looking for?

Most Recent

Policy Paper

Press

Blog

Report

Fact Sheet

Event

Resource

Pages

Leader

Author

Comment

not used title

not used title

MedMon_Catalyst_Banner.jpg

On Medicare Monday, we’ve talked a lot about how things have changed since 2006 and the implementation of Part D. We’ve looked at how Part D costs less than originally projected, how premiums have remained steady and how competition has worked to keep costs low.

We’ve also highlighted what the Medicare Trustees report has shown, that there has been a steady increase year after year in the generic utilization rate for Part D beneficiaries. In fact, in 2015, the use of generics increased to 86 percent, according to the Medicare Trustees report, up from 85 percent in 2014.

generics.png

A recent study published in the International Journal of Health Economics and Management took a closer look at the effect of the implementation of Part D, specifically at physician prescribing, and confirmed what the Medicare Trustees have found. According to the study, there has been “a 46% increase in the number of generic drugs prescribed or continued for the elderly after the introduction of Medicare Part D.”

When it comes to the impact of Part D, the facts speak for themselves. Since its implementation in 2006, the program has continued to ensure that beneficiaries have affordable access to the prescription medicines they need.

Learn more at PhRMA.org/PartD

Nicole Longo

Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Nicole Longo

Author Twitter

Author LinkedIn

What AARP isn’t telling seniors about MFN

August 24, 2026

CMS proposal could discourage patient-centered innovation

August 18, 2026

Nearly 1 in 4 patients initially denied access to IRA medicines

August 6, 2026

Medicare Part D at 20: Building on a strong foundation

July 23, 2026

Medicare Monday: New study further confirms increased use of generics after Part D

Part D

Medicare

Medicare Monday

Medicare Monday: New study further confirms increased use of generics after Part D

March 6, 2017

Medicare Monday: New study further confirms increased use of generics after Part D

Stay current on policy making

Sign up for email updates and follow us on social. 

About

Our Agenda

Policy Issues

Resources

Blog

Contact Us

Privacy Policy

Terms of Service

Facebook

Facebook

X

Twitter X

LinkedIn

LinkedIn

Instagram

instagram logo

America's Medicines

PhRMA Foundation

Voters for Cures

Working for Cures

Innovation.org

Please type your email

Success!

You've been added to the list